Keyphrases
Non-small Cell Lung Cancer Patients
100%
Pemetrexed
100%
Third Space
100%
Methotrexate
36%
Pleura
27%
Elimination Half-life
27%
Evacuation
18%
Hydrophilic Drug
9%
Pharmacokinetic Analysis
9%
Malignant Pleural Mesothelioma
9%
Pharmacokinetics
9%
Antifolate
9%
Plasma Samples
9%
Reversed-phase HPLC
9%
Plasma Protein Binding
9%
Volume Distribution
9%
Renal Impairment
9%
Perchloric Acid
9%
Steady State
9%
Current Recommendations
9%
Impaired Renal Function
9%
Limit of Quantification
9%
Liquid Sample
9%
Plasma Concentration
9%
Protein Precipitation
9%
Cytotoxic Drugs
9%
Sample Preparation
9%
Quantitative Determination
9%
Cancer Patients
9%
Drug Infusion
9%
Area under the Curve
9%
Non-small Cell Lung Cancer (NSCLC)
9%
Pharmacokinetic Parameters
9%
Two-compartment Model
9%
Volume of Distribution
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pemetrexed
100%
Non Small Cell Lung Cancer
100%
Methotrexate
36%
Elimination
36%
Volume of Distribution
18%
Pharmacokinetic
18%
Plasma Protein Binding
9%
Cytotoxic Agent
9%
Table Salt
9%
Pleura Mesothelioma
9%
Malignant Neoplasm
9%
Infection
9%
Pharmacokinetic Parameter
9%
Folic Acid Antagonist
9%
Perchloric Acid
9%
Reverse Phase High Performance Liquid Chromatography
9%